期刊
MABS
卷 1, 期 3, 页码 237-246出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.1.3.8352
关键词
cytokine blockers; dendritic cell; monoclonal antibodies; immunomodulators; T(H)2 cells; T(H)1 cells; airway inflammation; IgE; omalizumab
Asthma represents a syndrome of airway inflammatory diseases with complex pathology. The immunologic pathogenesis is being increasingly revealed and provides opportunity for targeted biological intervention. Current experience with immunomodulators as targeted therapy in asthma is described in this literature review. Targeted therapies have included strategies to activate dendritic cells through the TLR-9 receptors, to interrupt the action of T(H)2 cytokines with cytokine blockers and monoclonal antibodies, to promote development of TO responses, to block IgE mediated pathways and to block TNF alpha. Omalizumab is the only biological therapy that has an approved indication in asthma at this time. An improved understanding of the heterogeneity of asthma should allow for specific targeting of different disease phenotypes specific therapies including immunomodulators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据